糖尿病心肌纤维化药物治疗的研究进展-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

糖尿病心肌纤维化药物治疗的研究进展

Research progress in pharmacological treatment of diabetic myocardial fibrosis

ES评分 0 浏览量：67 下载量：0

DOI	10.12208/j.ijcr.20250194
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2025, 9(4)
作者	李继舟¹,李宏伟¹,李雅甜¹,张晔²,杨红玲²*,
作者单位	1 大理大学临床医学院云南大理,2 云南省第三人民医院云南昆明
摘要	糖尿病心肌纤维化是糖尿病心肌病的关键病理特征之一，可引发心脏舒张功能障碍，进而导致心力衰竭。本文系统地综述了糖尿病心肌纤维化药物治疗的研究进展，重点探讨了降糖药物、RAAS抑制剂、PPAR-α激动剂、TGF-β抑制剂、抗氧化剂和传统中药等治疗策略的最新研究进展。通过分析这些药物的作用机制和临床研究数据，指出其在改善心肌纤维化及心脏功能方面的潜力和未来研究方向。
Abstract	Diabetic myocardial fibrosis is a key pathological feature of diabetic cardiomyopathy. It can lead to diastolic dysfunction of the heart and, subsequently, heart failure. This article systematically reviews the research progress of pharmacological treatments for diabetic myocardial fibrosis, with a particular focus on the latest advancements in therapeutic strategies. These strategies include antihyperglycemic agents, RAAS inhibitors, PPAR-α agonists, TGF-β inhibitors, antioxidants, and traditional Chinese medicine. By analyzing the mechanisms of action and clinical research data of these drugs, their potential to improve myocardial fibrosis and cardiac function is highlighted. In addition, future research directions are proposed.
关键词	糖尿病心肌病；心肌纤维化；药物治疗；综述
KeyWord	Diabetic cardiomyopathy; Myocardial fibrosis; Pharmacological treatment; Review
基金项目
页码	87-91

参考文献
相关文献

[1] GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 published correction appears in Lancet. 2023 Sep30;402(10408):1132.
[2] Xu Y, Lu J, Li M, et al. Diabetes in China part 1: epidemiology and risk factors. Lancet Public Health. 2024;9(12):e1089-e1097.
[3] Meng L, Lu Y, Wang X, et al. NPRC deletion attenuates cardiac fibrosis in diabetic mice by activating PKA/PKG and inhibiting TGF-β1/Smad pathways. Sci Adv. 2023;9(31): eadd4222.
[4] Ritchie RH, Abel ED. Basic Mechanisms of Diabetic Heart Disease. Circ Res. 2020;126(11):1501-1525.
[5] 樊静珊.阿托伐他汀对2型糖尿病大鼠心肌RhoA/ROCK信号通路和纤维化的影响
[D].河北医科大学,2017.
[6] 高嘉梦,胡兵,申锷.心肌成纤维细胞转分化与糖尿病心肌病的研究进展
[J].中华心血管病杂志,2020,48(10):885-889.
[7] 张毅,李妍菲.糖尿病心肌纤维化研究进展
[J].湖北科技学院学报(医学版),2020,34(01):70-75.
[8] 丁小艳,吕丽丽,翟满满,等.糖尿病心肌病发病机制和治疗策略的研究进展
[J].中国糖尿病杂志,2024,32(09):710-714.
[9] Xu, X., et al. (2020). "Metformin improves cardiac function in a mouse model of diabetic cardiomyopathy by enhancing autophagy." *Cardiovascular Diabetology*, 19(1), 1-14.
[10] Wang, Y., et al. (2019). "Metformin attenuates cardiac fibrosis in diabetic cardiomyopathy by inhibiting the TGF-β1/Smad3 signaling pathway." *Journal of Cellular Physiology*, 234(6), 8836-8845.
[11] Zhou, G., et al. (2001). "Role of AMP-activated protein kinase in mechanism of metformin action." *Journal of Clinical Investigation*, 108(8), 1167-1174.
[12] Madiraju, A. K., et al. (2014). "Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase." *Nature*, 510(7506), 542-546.
[13] Wang Z, Huang L, Han L, et al. The protective effect of sodium-glucose cotransporter-2 inhibitor on left ventricular global longitudinal strain in patients with type 2 diabetes mellitus according to disease duration. Sci Rep. 2025;15(1):5111.
[14] 林浩,袁得强,陈飞,等.SGLT2抑制剂在冠心病中的作用机制的研究进展
[J].同济大学学报(医学版),2023,44(06):925-932.
[15] 李远翥,罗素新,黄毕.钠-葡萄糖协同转运蛋白2抑制剂对射血分数保留型心力衰竭的治疗进展
[J].中国心血管病研究,2023,21(08):757-762.
[16] 李兴红,金春娜.新型降糖药物SGLT2抑制剂和GLP-1受体激动剂的心血管获益研究进展
[J].心电与循环,2024, 43(05):524-529.
[17] 王凤梅,王波,宫志华,等.SGLT2抑制剂在心力衰竭治疗中的研究进展
[J].临床误诊误治,2024,37(21):96-100.
[18] Marso, S. P., et al. (2016). "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." *New England Journal of Medicine*, 375(4), 311-322.
[19] 王静,胡天晓.胰高血糖素样肽-1受体激动剂心血管获益研究进展
[J].浙江医学,2024,46(21):2241-2244+2259.
[20] Havranek B, Loh R, Torre B, Redfield R, Halegoua-DeMarzio D. Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes. Sci Rep. 2025;15(1):4947.
[21] Westermeier F, Fisman EZ. Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges. Cardiovasc Diabetol. 2025;24(1):44.
[22] 周子默,周驰,杨雅元,等.心肌纤维化的发病及治疗研究进展
[J].湖北科技学院学报(医学版),2022,36(05):452-456.
[23] 马艳红,陈冰,彭娇娇,等.ACE/ACE2失衡参与糖尿病心肌纤维化的形成
[J].徐州医科大学学报,2021,41(06):430-436.
[24] Oliveira-Junior SA, Martinez PF, Guizoni DM, et al. AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity. PLoS One. 2014;9(1):e86447.
[25] Hori Y, Touei D, Saitoh R, et al. The Aldosterone Receptor Antagonist Eplerenone Inhibits Isoproterenol-Induced Collagen-I and 11β-HSD1 Expression in Rat Cardiac Fibroblasts and the Left Ventricle. Biol Pharm Bull.2017;40(10):1716-1723.
[26] Wang L, Cai Y, Jian L, et al. Impact of peroxisome proliferator-activated receptor- α on diabetic cardiomyopathy
[J]. Cardiovasc Diabetol, 2021, 20(1):2.
[27] Wang X, Zhu XX, Jiao SY, et al. Cardiomyocyte peroxisome proliferator- activated receptor alpha is essential for energy metabolism and extracellular matrix homeostasis during pressure verload- induced cardiac remodeling
[J]. Acta Pharmacol Sin, 2022, 43(5):1231-1242.
[28] 王秋丽,张瑞英.PPARα在心血管疾病中作用机制的研究进展
[J].临床与病理杂志,2022,42(02):449-454.
[29] 吴晨方.PPAR-α/γ激动剂对代谢综合征心室重构的保护机制研究
[D].中南大学,2014.
[30] 李真真,白杨,黄婷.非诺贝特联合胰岛素治疗2型糖尿病合并非酒精性脂肪性肝病患者疗效观察
[J].肝脏,2022, 27(01): 103-105+122.
[31] Goumans MJ, Ten Dijke P. TGF-β Signaling in Control of Cardiovascular Function. Cold Spring Harb Perspect Biol. 2018;10(2):a022210.
[32] 马定虎,周宗涛,李政,等.ZLY18通过抑制TGF-β1/Smads通路改善血管紧张素Ⅱ诱导的心肌纤维化
[J].中国药理学通报,2023,39(02):229-238.
[33] Peng J, Yang K, Tian H, et al. The mechanisms of Qizhu Tangshen formula in the treatment of diabetic kidney disease: Network pharmacology, machine learning, molecular docking and experimental assessment. Phytomedicine. 2023;108: 154525.
[34] 邱羽菲,史嘉翊,宋旭东,等.心肌纤维化的发生机制及治疗研究进展
[J].心脏杂志,2021,33(05):553-557.
[35] Dastani M, Rahimi HR, Askari VR, et al. Three months of combination therapy with nano-curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double-blinded, placebo-controlled clinical trial. Biofactors. 2023;49(1):108-118.
[36] Jiang C, Li D, Chen L, et al. Quercetin ameliorated cardiac injury via reducing inflammatory actions and the glycerophospholipid metabolism dysregulation in a diabetic cardiomyopathy mouse model. Food Funct. 2022;13(14): 7847-7856.
[37] 李继舟,李宏伟,汤胜宇,等.金钗石斛多糖调节Plin5介导心肌细胞脂肪酸β氧化改善糖尿病大鼠心肌损伤
[J].昆明医科大学学报,2024,45(10):8-16.

引用本文

李继舟,李宏伟,李雅甜,张晔,杨红玲*. 糖尿病心肌纤维化药物治疗的研究进展 [J]. 国际临床研究杂志. 2025; 9; (4). 87 - 91.

文献评论

相关学者

相关机构